Evonik is all set to concentrate on its Metamino (DL-methionine) production at three of its world-scale hubs in Europe, Americas and Asia. With this move, the firm aims to strengthen its competitiveness in the market in terms of cost.

Under the terms of the licensing agreement, Atum’s Leap-In Transposase technology will be integrated into Rentschler’s in-house process to complement its existing cell line development offering. The technology platform is ideal for the production of standard antibodies as well as complex, multi-chain therapeutic proteins.

The new oral drug delivery technology – Eudratec Fasteric offers enteric protection and provides rapid release in the upper small intestine. The technology is capable of releasing 90 % of its dose within 30 minutes for effective targeting.

BASF has begun its first production of diphenylmethane diisocyanate (MDI) at its wholly-owned site in Chongqing. MDI production will support key industries in China’s western areas.

Messer will secure its leading position in Chinese specialty gases market and now also produces specialty gases in the eastern Chinese city of Suzhou, in Jiangsu province. Therefor the industrial gases specialist invests €33 million.

Under the terms of the agreement, Technip FMC and Mc Phy will work together to develop hydrogen technology and address commercial opportunities. Technip FMC has also made an equity investment in Mc Phy.

Messer’s new plant is expected to produce 2,400 tonnes of oxygen, nitrogen and argon per day. With this project, the company plans to expand its business in Spain and further strengthen its presence in Western Europe.

Chevron Phillips Chemical (CP Chem) has become the first company in the US to produce circular polyethylene from recycled mixed-waste plastics on a commercial scale. Utilising advanced recycling technology, the firm has plans to develop its new circular polyethylene range and market it upon certification.

Sartorius offers technologies for every phase of the biopharmaceutical value-added chain – having already recognized the potential of biopharmaceuticals at quite an early stage, the company has since carefully aligned its product and service portfolio with the requirements of the industry. Today, Sartorius presents its capabilities as an innovative solution provider for biopharmaceutical research and industry.

Under the terms of the contract, Lummus Technology will be responsible for designing as well as supplying four proprietary Short Residence Time VI and VII type cracking furnaces to the gas chemical complex in Uzbekistan.